Elsevier

Ophthalmology

Volume 108, Issue 8, August 2001, Pages 1409-1414
Ophthalmology

INTACS inserts for treating keratoconus: One-year results

Presented in part at the American Academy of Ophthalmology annual meeting, Dallas, Texas, October 2000.
https://doi.org/10.1016/S0161-6420(01)00646-7Get rights and content

Abstract

Objective

To evaluate the use of INTACS micro-thin prescription inserts (Kera Vision, Inc., Fremont, CA) for the treatment of keratoconus.

Design

Prospective, nonrandomized (self-controlled) comparative trial.

Participants/intervention

Ten patients from our prospective clinical study who had completed 12 months of follow-up were evaluated. All patients had keratoconus with clear central corneas and were contact lens intolerant. After reviewing corneal pachymetry and topography of individual patients, INTACS inserts of 0.45-mm thickness were placed in the inferior cornea to lift the cone and INTACS of 0.25-mm thickness were inserted superiorly to counterbalance and flatten the overall anterior corneal surface.

Main outcome measures

Differences between preoperative and postoperative uncorrected visual acuity, best spectacle-corrected visual acuity, manifest refraction, and keratometry values were statistically assessed. Changes in corneal ectasia were evaluated by reviewing corneotopographic maps.

Results

No intraoperative complications occurred in this series of patients. Spherical equivalent error and refractive astigmatism were reduced with INTACS inserts treatment. Postoperative month 12 uncorrected visual acuity (logarithm of the minimum angle of resolution [logMAR] mean, 0.35, standard deviation [SD], 0.16 [∼20/50, ∼2 lines]) was significantly better than preoperative (logMAR mean, 1.05; SD, 0.33 [∼20/200, ∼3 lines]; P ≤0.05). Average best spectacle-corrected visual acuity at postoperative month 12 was improved by approximately two lines compared with baseline (logMAR mean, 0.22; SD, 0.12 [∼20/32, ∼1 line]; logMAR mean, 0.38; SD, 0.13 [∼20/50, ∼1 line], respectively). Topographic corneal shape (size and height of the cone) was improved for all subjects after insert placement.

Conclusions

INTACS micro-thin prescription inserts seem to provide a viable method for treating clear corneal keratoconus for patients who are contact lens intolerant. The corneal steepening and astigmatism associated with keratoconus were reduced, and visual acuity was improved with treatment in almost all eyes.

Section snippets

Patients and methods

All patients included in this study were referred to our institution for PK to treat keratoconus. Enrolled patients had keratoconus with clear central cornea and were contact lens intolerant. Patients had best spectacle-corrected visual acuity of 20/100 or better in the treatment eye and corneal thickness of 400 μm or more at the location where INTACS inserts were to be placed. When both eyes of a patient were eligible for study enrollment, the eye with the worse visual acuity was included for

Results

The average age of the patients was 30.9 ± 6.1 years. No intraoperative complications occurred in this patient series; both inferior and superior intrastromal tunnels for placement of INTACS inserts were made without any technical problems. INTACS inserts were removed 2 months postoperatively from one patient eye currently enrolled in our prospective clinical series (n = 23) because of superficial placement. INTACS inserts were removed easily under topical anesthesia, after opening the original

Discussion

The objective of using INTACS inserts for treating keratoconus is not to eliminate the corneal disease but to decrease corneal abnormality associated with it and improve visual acuity in affected patients to satisfactory levels. An important potential benefit of treating keratoconus with INTACS inserts is to delay or eliminate the need for a corneal graft. Postoperative results of our series of patients demonstrated that spherical equivalent error and astigmatism were significantly reduced and

References (18)

There are more references available in the full text version of this article.

Cited by (224)

  • CLEAR – Medical use of contact lenses

    2021, Contact Lens and Anterior Eye
View all citing articles on Scopus
1

Debby Holmes-Higgin is an employee of KeraVision, Inc.

View full text